Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

IVAC-RCC-001: A Personalized Neoantigen Vaccine as Add-on to Standard of Care Checkpoint Inhibitor in Advanced/Metastatic RCC Patients

NCT05641545 is registered in ClinicalTrials.gov with SLK Kliniken Heilbronn GmbH as lead sponsor.

NCT NCT05641545
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05641545 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
IVAC-RCC-001: A Personalized Neoantigen Vaccine as Add-on to Standard of Care Checkpoint Inhibitor in Advanced/Metastatic RCC Patients
Lead sponsor
SLK Kliniken Heilbronn GmbH
Phase
Phase 1
Overall status
Terminated
Start date
October 17, 2022
Completion date
September 15, 2024
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced renal cell carcinoma